Latham & Watkins Advises Blackstone Life Sciences on US$750 Million R&D Funding Agreement, the Largest R&D Funding Agreement in 2026
Blackstone Life Sciences will provide $750M to Johnson & Johnson for Phase 3 trials of OLN324, a retinal disease therapy. The funding follows the expected acquisition of Ollin Biosciences. Latham & Watkins advised Blackstone on the deal.
How this was made
The 30-second read
Why it matters
A $750 million R&D funding agreement is a concrete financing catalyst for J&J’s OLN324 Phase 3 program, potentially lowering development funding risk and supporting pipeline continuity through late-stage execution.
Market read
Traders may reassess J&J’s near-term pipeline financing risk and the perceived momentum of its late-stage retinal program.
What to watch
Key details like economics (repayment, royalties, dilution, covenants) are not provided here, which could materially affect net value to J&J beyond headline funding size.
Background
The piece is a law-firm transaction note describing Blackstone Life Sciences providing development funding to Johnson & Johnson for Phase 3 of OLN324 after the expected closing of Blackstone’s acquisition of Ollin Biosciences.
Ticker impact
Blackstone Life Sciences funds provide $750 million for Johnson & Johnson to finance Phase 3 development of OLN324 for retinal vascular diseases.
Likely modest positive bias as investors price lower funding risk and improved probability of progressing OLN324 through Phase 3.
The article discloses a large, specific $750 million R&D funding arrangement tied to J&J’s Phase 3 program, which is directionally supportive, though it is not a direct earnings or regulatory milestone.
Market effects
Highlights continued availability of structured healthcare finance for late-stage biotech-style development within large pharma pipelines.
Limited direct regional market linkage; primarily US healthcare capital markets sentiment.
Moderate, as it reflects cross-border style healthcare finance structures that can influence global biotech/pharma funding expectations.
Counterpoint
The funding may not change clinical or regulatory outcomes, so equity reaction could be muted if investors view it as financial engineering rather than a science catalyst.
Key entities
- companyJohnson & Johnson
Receives $750 million in development funding to support Phase 3 clinical development of OLN324.
- fund/managerBlackstone Life Sciences
Provides the $750 million development funding via funds it manages.
- companyOllin Biosciences, Inc.
Acquisition by Blackstone is referenced as expected to close before the funding supports OLN324 Phase 3.
- investigational therapyOLN324
Investigational therapy for serious retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema.